MA-EVERBRIDGE
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management and enterprise safety software applications to help keep people safe and businesses running faster, has announced the completion of its acquisition of Unified Messaging Systems ASA ("UMS"). Based in Oslo, Norway, UMS provides a unique countrywide mobile population alerting system globally and is also one of the leading critical communications providers in Europe. By uniting UMS’s proven mobile alerting, crisis management, and notification applications with Everbridge’s market-leading Critical Event Management (CEM) software platform, the acquisition creates an unparalleled set of solutions to help customers assess threats, initiate and manage incidents, and notify stakeholders from a local neighborhood or building to a countrywide level, and across the globe.
UMS’s Population Alerting System (PAS) provides 2-way SMS broadcast capabilities to an entire mobile population. To accomplish this, UMS has the unique ability to message the mobile phones of anyone connected to a carrier’s cell towers. The company also provides Location-Based Alerting technology which enables municipalities to geographically pinpoint where to send notifications within a region. This capability is equally applicable for national and global companies who want to reach local and traveling employees, automating the alert by preferred language. UMS’s PAS systems are deployed in a number of countries, providing countrywide alerting to Sweden, Norway, the Netherlands, the Bahamas, Singapore, Greece, and Cambodia, as well as in the city of Kiev, and some of the largest states in India.
As one of the leading mass notification providers internationally, UMS significantly increases Everbridge’s international reach. UMS supports, for example, over 1,200 customers in Northern Europe and reaches over 500 million people globally via population alerting. Its crisis and emergency management product Previstar is used for planning and resource management purposes by major public safety agencies in such places as Virginia, Georgia, Massachusetts, West Bengal in India, as well as by the U.S. Navy. Previstar will considerably enhance Everbridge’s crisis management capabilities.
“We are thrilled to welcome UMS to the Everbridge family, accelerating our international growth and creating the most comprehensive Critical Event Management platform for business, state and local government, and now entire countries,” said Jaime Ellertson, CEO of Everbridge. “UMS provides Everbridge with a passionate and customer-focused team of experts, differentiated technology, and a shared mission to keep people safe and businesses running during a critical event.”
Together, Everbridge and UMS form a global team of over 700 employees dedicated to delivering innovative, differentiated solutions for critical event management. The collective entity expands Everbridge’s international expertise in business continuity, emergency response, and critical event planning, while providing UMS customers access to Everbridge’s Critical Event Management platform for improved messaging scale and delivery across the world.
“Everbridge’s extensive technical capabilities, the breadth of its offerings, and the experience of its global team made for a natural fit with UMS,” said Espen Gylvik, Chief Executive Officer, UMS. “We look forward to aligning with the market leader to provide critical services and innovative communication solutions to make a significant difference in people’s lives.”
The acquisition values the total share capital of UMS at approximately NOK 268 million, or approximately USD $33.6 million.
About Everbridge
Everbridge,
Inc.
(NASDAQ: EVBG) is a global software company that provides
enterprise software applications that automate and accelerate
organizations’ operational response to critical events in order to keep
people safe and businesses running faster. During public safety threats
such as active shooter situations, terrorist attacks or severe weather
conditions, as well as critical business events such as IT outages,
cyber-attacks or other incidents such as product recalls or supply-chain
interruptions, over 3,700 global customers rely on the company’s
SaaS-based platform to quickly and reliably aggregate and assess threat
data, locate people at risk and responders able to assist, automate the
execution of pre-defined communications processes, and track progress on
executing response plans. The company’s platform sent over 2 billion
messages in 2017 and offers the ability to reach more than 200 countries
and territories with secure delivery to over 100 different communication
devices. The company’s critical communications and enterprise safety
applications include Mass Notification, Incident Management, Safety
Connection™, IT Alerting, Visual Command Center®, Crisis Commander®,
Community Engagement™ and Secure Messaging. Everbridge serves 9 of the
10 largest U.S. cities, 8 of the 10 largest U.S.-based investment banks,
25 of the 25 busiest North American airports, six of the 10 largest
global consulting firms, six of the 10 largest global auto makers, all
four of the largest global accounting firms, four of the 10 largest
U.S.-based health care providers and four of the 10 largest U.S.-based
health insurers. Everbridge is based in Boston and Los Angeles with
additional offices in San Francisco, Lansing, Orlando, Beijing, London,
and Stockholm For more information, visit www.everbridge.com
,
read the company blog
,
and follow on Twitter
and Facebook
.
Cautionary Language Concerning Forward-Looking Statements
This
press release contains “forward-looking statements” within the meaning
of the “safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including but not limited to, statements regarding
the anticipated opportunity and trends for growth in our critical
communications and enterprise safety applications and our overall
business, our market opportunity, our expectations regarding sales of
our products, and our goal to maintain market leadership and extend the
markets in which we compete for customers. These forward-looking
statements are made as of the date of this press release and were based
on current expectations, estimates, forecasts and projections as well as
the beliefs and assumptions of management. Words such as “expect,”
“anticipate,” “should,” “believe,” “target,” “project,” “goals,”
“estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,”
variations of these terms or the negative of these terms and similar
expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which involve factors or circumstances that are
beyond our control. Our actual results could differ materially from
those stated or implied in forward-looking statements due to a number of
factors, including but not limited to: our ability to successfully
integrate businesses and assets that we may acquire; the ability of our
products and services to perform as intended and meet our customers’
expectations; our ability to attract new customers and retain and
increase sales to existing customers; our ability to increase sales of
our Mass Notification application and/or ability to increase sales of
our other applications; developments in the market for targeted and
contextually relevant critical communications or the associated
regulatory environment; our estimates of market opportunity and
forecasts of market growth may prove to be inaccurate; we have not been
profitable on a consistent basis historically and may not achieve or
maintain profitability in the future; the lengthy and unpredictable
sales cycles for new customers; nature of our business exposes us to
inherent liability risks; our ability to attract, integrate and retain
qualified personnel; our ability to maintain successful relationships
with our channel partners and technology partners; our ability to manage
our growth effectively; our ability to respond to competitive pressures;
potential liability related to privacy and security of personally
identifiable information; our ability to protect our intellectual
property rights, and the other risks detailed in our risk factors
discussed in filings with the U.S. Securities and Exchange Commission
(“SEC”), including but not limited to our Annual Report on Form 10-K for
the year ended December 31, 2016 filed with the SEC on March 23, 2017.
The forward-looking statements included in this press release represent
our views as of the date of this press release. We undertake no
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise. These forward-looking statements should not be relied upon as
representing our views as of any date subsequent to the date of this
press release.
All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410005436/en/
Contact:
Media Contact:
Everbridge
Jeff Young, 781-859-4116
jeff.young@everbridge.com
or
Investor
Contact:
ICR
Garo Toomajanian, 818-230-9712
ir@everbridge.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
